Bighatbiosciences
Senior Scientist, Developability [Contract]
San Mateo, CA, CAOnsite · United States
Senior · Contract / Temp · Lab Science
age unknown
$123k–$197kno pay posted
$123k$197k
- Market p25–p75
- $130k–$195k
- Bighatbiosciences p25–p75
- $123k–$197kn=8
15open roles
- Opened · 30d
- +0
- Closed · 30d
- −0
29,070open · Senior Other
- Opened · 7d
- +3,07911% of open
- All other
- 623,327open
The role: BigHat Biosciences is looking for a hands-on, bench-driven scientist to perform IND-enabling developability assessments on late stage drug candidates from our Milliner Platform for AI-designed therapeutics. This is a lab-based 12-month contract role, with the possibility but no guarantee of conversion to full-time position. You'll spend the majority of your time at the bench executing complex stability studies.
Responsibilities
- Lead, design, and execute in-use dose solution studies to assess drug compatibility with administration materials.
- Develop highly sensitive protein characterization methods (qSEC, RP-HPLC, CEX, particle counting, etc) for assessing drug quality and recovery.
- Support late-stage characterization, including formulation screening, stress testing, and peptide mapping, to rank and advance lead candidates.
- Drive developability assessments (purity, stability, tolerability, biophysical properties) across programs, with strong attention to data interpretation and organization.
- Communicate with and manage external CROs for testing and analytics.
- Interpret and communicate scientific findings, propose next steps, and broadcast clearly across the organization.
- Proactively identify and scope state-of-the-art analytical tools and developability technologies.
Skills
- PhD in Biochemistry or relevant discipline with 5+ year(s) of industry experience; exceptional non-PhD candidates with deep bench experience will be considered.
- Experience developing and optimizing sensitive analytical chromatography-based methods is a must.
- Strong background in biophysical and analytical characterization of antibodies and antibody fragments: SEC, HIC, CE-SDS, DLS, DSF, ELISA, LC-MS.
- Track record of translating complex data into clear results and recommended actions.
- Enthusiastic about learning and onboarding new technologies to expand capabilities and improve work quality, timelines, throughput or cost.